Madison, WI – According to filings with the U.S. Securities and Exchange Commission, Elephas Biosciences is raising $43,500,023.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Maneesh Arora played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Elephas Biosciences
Cancer is a leading cause of death worldwide, with the number of patients projected to triple by 2060. Despite recent advances in precision medicine and a significant increase in the number of available therapies, only 1 in 3 patients receiving therapy respond. Elephas is solving this problem by developing an imaging platform technology to assess how live tumor fragments respond to cancer therapies. We are removing the trial-and-error approach to cancer care by harnessing the latest advances in cancer biology, multimodal microscopy, and artificial intelligence to accelerate drug development and empower clinical decision making. Our unique approach maintains the native 3-dimensional cellular architecture and micro-environment of the patients tumor, enabling rapid real-time profiling of live tumor samples with immuno-oncology agents, targeted therapies, chemotherapy, and cell therapies.

To learn more about Elephas Biosciences, visit http://elephas.com/

Contact:
Maneesh Arora, President and Chief Executive Officer
608-622-7954

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved